Administration (FDA) approved Ibandronate as a daily, 2.50mg dose treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized , double-blind , placebo -controlled trial of 2,946 women suffering post-menopausal osteoporosis. The participants received either a placebo or an oral ibandronate dose (2.50mg), or intermittently (20mg every second